The Behnke Group

🚨 Game-Changing Innovation in Gastric Cancer Detection 🚨 We’re thrilled to share the latest advancement from Cizzle Bio, Inc.: the DEX-G2 Gastric Cancer Blood Test! Gastric cancer is the second most lethal cancer globally, often detected too late. Cizzle Bio’s DEX-G2 is here to change that. 🔬 Key Features of DEX-G2: ✅ 95% Sensitivity & 97% Specificity for early-stage detection ✅ Non-invasive: A simple blood draw replaces traditional endoscopy ✅ Dual biomarker approach combining cell-free and exosomal miRNAs This breakthrough will help: - Patients: Get diagnosed earlier with fewer invasive procedures. - Clinicians: Access accurate, fast results seamlessly. - Healthcare Systems: Implement scalable, cost-effective screening solutions. As DEX-G2 gears up for a full launch in early 2025, it marks another step in Cizzle Bio’s mission to Detect Early, Save Lives. 📢 Learn more about how this innovation is transforming cancer detection: Read the full story here: https://buff.ly/3P1G4fb #CizzleBio #GastricCancerDetection #DEXG2 #InnovationInHealthcare #EarlyDetection

🚨 Exciting News in Early Lung Cancer Detection 🚨 The Behnke Group is proud to support Cizzle Bio, Inc. in their groundbreaking partnership to bring the CIZ1B biomarker test for early lung cancer detection to North America! This exclusive licensing and partnership agreement is a major step toward improving healthcare outcomes and saving lives. With a $300,000 initial royalty payment and guaranteed future royalties, Cizzle Bio, Inc. is poised to make a real impact in the USA and Canada. 🔑 Key Highlights: - Exclusive rights to the CIZ1B biomarker technology in North America - Collaboration with top cancer centers like Moffitt Cancer Center - Revenue streams to drive future growth and innovation We’re excited to be part of this journey as Cizzle Bio, Inc. works towards a full market launch in April 2025, making life-saving early cancer detection more accessible. Learn more about this strategic partnership and how it’s transforming lung cancer detection. https://buff.ly/3YtVCxM #HealthcareInnovation #LungCancerDetection #BiotechNews #EarlyDetection #TheBehnkeGroup #CizzleBio #StrategicPartnerships #LifeSavingTechnology

🌐 Supporting Innovation in Cancer Detection! 🌐 The Behnke Group is proud to see Cizzle Bio, Inc., led by our very own Bill Behnke, CEO, collaborate with Moffitt Cancer Center to push the boundaries of lung cancer detection. The use of the CIZ1B biomarker test could be a game-changer in early diagnosis and treatment. Congratulations to the teams at Cizzle Bio, Inc. and Moffitt Cancer Center for this groundbreaking partnership. Here's to a future where early detection saves more lives! 🩺🔬 #Innovation #Healthcare #CancerResearch #Leadership #BehnkeGroup #CizzleBio #MoffittCancerCenter

Advancing Early Detection of Lung Cancer: A Call to Action Lung cancer remains the leading cause of cancer deaths in the U.S., yet only 6% of high-risk individuals get screened. Discover the importance of lung cancer screening, the barriers people face, and how Cizzle Bio, Inc. is pioneering early detection with their innovative CIZ1B biomarker test. Learn more about this crucial health issue and Cizzle Bio's efforts to save lives through early detection. Read the full article: https://buff.ly/3WjvYcK #LungCancerAwareness #EarlyDetection #HealthcareInnovation #BehnkeGroup

📢 Exciting News! Cizzle Bio, Inc. has entered a strategic partnership with BBI Solutions to supply its first order of proprietary monoclonal antibodies for early-stage lung cancer detection. This collaboration marks a significant milestone in our mission to commercialize the CIZ1B biomarker test. Key Highlights: - Partnership with BBI Solutions - Certified manufacturing in ISO 13485 facilities - Initial batch supports up to 5000 tests - Facilitating clinical evaluations with a major US cancer center Read more: https://buff.ly/3WrX3eV #LungCancer #CancerDetection #Biotechnology #HealthcareInnovation

🫁 Lung Cancer Screening: An Essential Guide Recent research highlights the importance of early lung cancer detection. Despite recommendations, screening rates remain low, especially in high-risk populations. Key Points: - Eligibility: Adults aged 50-80 with a significant smoking history. - Benefits and Risks: Early detection vs. potential risks like false positives. - Cizzle Bio’s Contribution: Our CIZ1B biomarker test is a non-invasive, accurate alternative, aiming to improve screening rates and early diagnosis. Read more about Lung Cancer Screening: An Essential Guide: https://buff.ly/4cUPao4 #LungCancer #EarlyDetection #Healthcare #Biotechnology #CizzleBio #TheBehnkeGroup

Understanding Low Lung Cancer Screening Rates in the US Recent research from JAMA Network highlights the ongoing challenges in lung cancer screening across the US. In 2022, only 18% of eligible individuals were up to date with lung cancer screenings (LCS). Rates are particularly low in southern states with high lung cancer mortality rates. Key Findings: - Low nationwide screening rates (9.7%-31% across states) - Socioeconomic and access disparities - Higher screening rates in states with Medicaid expansion and higher LCS capacity These findings underscore the need for improved healthcare access and increased screening capacity. Read the full article for more details:

🚀 Overcoming Barriers in Lung Cancer Screening: Insights from Recent Research 🩺 Recent studies emphasize the critical barriers in lung cancer screening, including socioeconomic factors and access to technology. Addressing these challenges is crucial for early diagnosis and treatment. At The Behnke Group, we support Cizzle Bio, Inc.'s mission to improve lung cancer screening through the innovative CIZ1B biomarker test. This test aims to make screening more accessible and effective for everyone. 🔗 Read the full article to learn more: https://buff.ly/4cYBnNg #HealthcareInnovation #LungCancerAwareness #EarlyDetection #Biotechnology #CizzleBio

Transforming Lung Cancer Detection: Cizzle Biotechnology's Breakthrough Exciting news from Cizzle Biotechnology as they unveil a revolutionary blood test that utilizes the CIZ1B biomarker for early detection of lung cancer. Allan Syms discusses the innovative finger-prick test and strategic partnerships that aim to expand screening capabilities to the UK and Europe, ensuring broader access and improved patient outcomes. Discover the details of this significant advancement by watching the full video on our site. 🔗 Watch Now: https://buff.ly/4bD9Wr7 #LungCancerDetection #Innovation #Healthcare

Major Milestone Achieved: Cizzle Bio's CIZ1B Test Selected for U.S. Cancer Study Exciting news from Cizzle Bio! Our CIZ1B biomarker test has been selected for a significant clinical study at a leading U.S. cancer center. This milestone not only underscores the potential of our innovative technology in early lung cancer detection but also sets the stage for transformative changes in healthcare diagnostics. Read more about this groundbreaking development and what it means for the future of lung cancer detection on our latest blog post: https://buff.ly/4eVkR28 #CizzleBio #CancerResearch #InnovationInHealthcare #LungCancerAwareness